Major Depressive Disorder _MDD_ - Drug Pipeline Analysis and Market Forecasts to 2015

					Original                      Source:                     Drug                    Market
http://www.sandlerresearch.org/reports/15763-major-depressive-disorder-mdd-drug-pi
peline-analysis-and-mark.html
  Buy                      Now:                      Market                     Research
http://www.sandlerresearch.org/reports/15763-major-depressive-disorder-mdd-drug-pi
peline-analysis-and-mark.html
  Browse           all          :         Pharmaceut            Market          Research
http://www.sandlerresearch.org/market-research/pharmaceuticals/
  GlobalData, the industry analysis specialist, has released its new report, 鈥淢 ajor
Depressive Disorder - Pipeline Assessment and Market Forecasts to 2017 鈥? The
report is an essential source of information and analysis on the global Major
depressive Disorder (MDD) therapeutics market. The report identifies the key trends
shaping and driving the global MDD therapeutics market. The report also provides
insights into the competitive landscape and the emerging players expected to
significantly alter the positions of the existing market leaders. Most importantly, the
report provides valuable insights into the pipeline products within the global MDD
sector. This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GlobalData 鈥檚
team of industry experts.
  GlobalData estimates the global MDD therapeutics market to be valued at $11.02bn
in 2009. The market is estimated to decline by 3% to $9.0bn in 2017, which is
attributed to patent expiry of Lexapro and Cymbalta in 2012 and 2013. However, the
MDD market is anticipated to stabilize with the expected approval of Vilazodone and
TC-5214 and the increasing public awareness.
  Scope
  The scope of the report includes:
  Annualized global Hepatitis B therapeutics market revenue data from 2001 to 2009,
forecast for eight years to 2017.
  Geographies covered in this report include the United States (US), the United
Kingdom (UK), Italy, Spain, Germany, France and Japan.
  Pipeline analysis data providing a split across different phases, mechanisms of action
being developed and emerging trends. The key classes of mechanism of action include
selective serotonin reuptake inhibitor, serotonin and nenorepinephrine reuptake
inhibitor, cortiocotropin releasing factor antagonist and AMPA receptor modulator.
  Analysis of the current and future market competition in the global MDD
therapeutics market. The key future market players covered are GlaxoSmithkline,
AstraZeneca, Forest Laboratories, Merck & Co., Eli Lilly, Weyth (Pfizer) and
Lundbeck.
  Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
  Key topics covered include a strategic competitor assessment, a market
characterization, the unmet needs and the implications for the MDD therapeutics
market.
  Reasons to buy
  The report will enhance your decision making capability. It will allow you to:
  Develop and design your in-licensing and out-licensing strategies through a review
of pipeline products and technologies and by identifying the companies with the most
robust pipelines.
  Develop business strategies by understanding the trends shaping and driving the
global MDD therapeutics market.
  Drive revenues by understanding the key trends, innovative products and
technologies, market segments and companies likely to affect the global MDD
therapeutics market in the future.